Approvals/TGA/FLUZONE HIGH-DOSE QIV inactivated quadrivalent influenza vaccine (Split Virion) influenza virus haemagglutinin 240 mcg, suspension for injection PFS, SH2025 Season

Approved

STANDARD

FLUZONE HIGH-DOSE QIV inactivated quadrivalent influenza vaccine (Split Virion) influenza virus haemagglutinin 240 mcg, suspension for injection PFS, SH2025 Season

Sanofi-Aventis Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Date: May 30, 2025
Approval ID: 6a85c78a2d3d533a
Company: Sanofi-Aventis Australia Pty Ltd
Type: Standard

Approval Details

Approval Id: 6a85c78a2d3d533a
Product Name: FLUZONE HIGH-DOSE QIV inactivated quadrivalent influenza vaccine (Split Virion) influenza virus haemagglutinin 240 mcg, suspension for injection PFS, SH2025 Season
Artg Id: 320962
Artg Name: FLUZONE HIGH-DOSE QIV inactivated quadrivalent influenza vaccine (Split Virion) influenza virus haemagglutinin 240 mcg, suspension for injection PFS
Sponsor: Sanofi-Aventis Australia Pty Ltd
Company Detail Path: /organization/sanofi-aventis-australia-pty-ltd
Artg Date: 2020-07-31
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/b57af11ad32bf70a89e32f8b8d719d07.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/a46a8b099baa44136b3233efabe178a7.pdf

Active Ingredients

Approved

Quick Info

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

6a85c78a2d3d533a

Type

Standard

Back to TGA Approvals